Drugs / EG-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05170048 | Jun 2026 → Jun 2028 expected | dry age related macular degeneration | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05170048 ↗ |
| Route | Oral | “The investigation drug, EG-301 Tablets 150mg, is for oral use.” NCT05170048 ↗ |